Genomic and molecular testing for myeloid and lymphoid neoplasms.
Molecular testing in haematological malignancy supports diagnosis, risk stratification and the identification of targetable alterations, and is reported alongside morphological, immunophenotypic and cytogenetic findings.
Documented capability
Myeloid next-generation sequencing panels
Chronic lymphocytic leukaemia panel
IGHV somatic hypermutation status
T-cell and B-cell receptor repertoire and clonality assessment
Leukaemia and lymphoma NGS, including gene fusions
JAK2, CALR and MPL testing
Quantitative PCR for recurrent fusion transcripts
This page is informational. It does not accept requests, samples, patient data or
genomic files, and provides no result lookup.